Effect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus.

ABSTRACT: Aims/Introduction:? Mitiglinide is the newest drug in the meglitinide family. It increases the early-phase insulin release through rapid association-dissociation kinetics in the pancreatic ? cells. The efficacy and safety of adding meglitinide to metformin monotherapy in patients with type 2 diabetes are unknown.? We carried out a prospective, randomized, multicenter trial to assess the efficacy and safety of combined treatment with mitiglinide and metformin for patients with type 2 diabetes who showed inadequate glycemic control with metformin monotherapy. Subjects with glycated hemoglobin (HbA1c) >7.0% after an 8-week metformin run-in phase were randomized to a 16-week trial phase with metformin plus mitiglinide (Met?+?Mit) or metformin plus placebo (Met?+?Pcb).? Compared with the Met?+?Pcb group, the Met?+?Mit group showed a greater reduction in HbA1c (-0.7?±?0.6%vs-0.4?±?0.7%, P?=?0.002), fasting plasma glucose (-0.77?±?1.76?mmol/L vs-0.05?±?1.60?mmol/L, P?=?0.015) and 2-h postprandial glucose (-3.76?±?3.57?mmol/L vs-0.84?±?3.07?mmol/L, P?

SUBMITTER: Cho YM 

PROVIDER: S-EPMC4008006 | biostudies-literature | 2010 Aug

REPOSITORIES: biostudies-literature